A clinical study at Seoul National University Hospital for CART-T (Chimeric Antigen Recepter-T cell) treatment for pediatric leukemia patients was first approved.

This is the first approval since the enforcement of the "The Act on the “Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals” (hereinafter Advanced Bio Act)" in September last year.

The MOHW (Minister Kwon Deok-cheol) and the MFDS (Minister Kim Kang-rip) announced on the 8th that the clinical research plan applied by Seoul National University Hospital (Professor Kang Hyung-jin) was approved as the first high-risk high-tech regenerative medical clinical study since the implementation of the "Adva